[{"from": "human", "value": "Please give me some details about this molecule. [C][C@H1][C@@H1][Branch2][Branch1][=Branch2][C@][Branch2][Ring2][S][C][C@H1][Branch2][Ring1][Branch2][C@][Branch2][Ring1][Ring1][C@H1][C@@][Ring1][Branch2][Branch1][#Branch1][C][C][C][Ring1][=Branch1][C][C][C][C][Ring1][=Branch2][=O][C][O][C][=Branch1][C][=O][C][S][C@@H1][C][C][C@H1][Branch1][=Branch1][C][C@H1][Ring1][=Branch1][O][N][Branch1][C][C][C][=C][O]"}, {"from": "gpt", "value": "The molecule is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019.  This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity."}]